Heron Therapeutics entered into Amendment No. 1 to its Tax Benefit Preservation Plan on August 13, 2026, extending the plan's Final Expiration Date from August 14, 2026, to August 14, 2029. This modification preserves the company's ability to utilize net operating loss carryforwards by adjusting the timeline of its shareholder rights agreement. Heron Therapeutics operates in the biopharmaceutical industry and develops treatments for pain management.

Heron Therapeutics reported Q2 2026 net revenue of $37.7 million and ended the quarter with $42.7 million in cash. The company amended its credit facility with Hercules Capital, reducing outstanding principal by $13.5 million immediately and potentially another $4 million by September 15, 2026. Heron withdrew its full-year 2026 financial guidance due to a Delaware court patent decision affecting CINVANTI sales forecasts and paused planned sales force expansion. Management stated the company is considering strategic alternatives while tightening spending. Heron Therapeutics operates in the biotechnology industry, developing and commercializing therapeutic innovations for acute care and oncology patients.

On June 25, 2026, Heron Therapeutics received notice from Nasdaq that it failed to meet the minimum $1.00 bid price requirement for continued listing, as the closing price remained below this threshold from May 12, 2026, to June 24, 2026. The company has until December 22, 2026, to regain compliance, which requires a closing bid price of at least $1.00 for ten consecutive business days. If compliance is not achieved, the company may seek an additional 180-day extension, potentially through a reverse stock split. The company operates in the biotechnology industry and develops and commercializes pharmaceutical products.

At its 2026 Annual Meeting of Stockholders on June 11, 2026, Heron Therapeutics approved several key proposals. Stockholders authorized an increase of 16,560,000 shares for the 2007 Amended and Restated Equity Incentive Plan and an additional 10,000,000 shares for the 1997 Employee Stock Purchase Plan. The company also ratified the adoption of a Tax Benefits Preservation Plan on a nonbinding advisory basis. Additionally, stockholders elected seven directors, ratified the appointment of Withum Smith+Brown, PC as the independent auditor for fiscal year 2026, and approved executive compensation for 2025 on a nonbinding advisory basis. Heron Therapeutics is a biopharmaceutical company that develops and commercializes medicines for the treatment of pain and other medical conditions.

Heron Therapeutics announced that a U.S. District Court ruled on June 1, 2026, that its U.S. Patent Nos. 12,115,255 and 12,290,520, which cover CINVANTI, are invalid. The company intends to appeal this decision to the United States Court of Appeals for the Federal Circuit.